Your browser doesn't support javascript.
loading
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.
Elez, Elena; Ros, Javier; Fernández, Jose; Villacampa, Guillermo; Moreno-Cárdenas, Ana Belén; Arenillas, Carlota; Bernatowicz, Kinga; Comas, Raquel; Li, Shanshan; Kodack, David Philip; Fasani, Roberta; Garcia, Ariadna; Gonzalo-Ruiz, Javier; Piris-Gimenez, Alejandro; Nuciforo, Paolo; Kerr, Grainne; Intini, Rossana; Montagna, Aldo; Germani, Marco Maria; Randon, Giovanni; Vivancos, Ana; Smits, Ron; Graus, Diana; Perez-Lopez, Raquel; Cremolini, Chiara; Lonardi, Sara; Pietrantonio, Filippo; Dienstmann, Rodrigo; Tabernero, Josep; Toledo, Rodrigo A.
Affiliation
  • Elez E; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. meelez@vhio.net.
  • Ros J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. meelez@vhio.net.
  • Fernández J; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Villacampa G; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Moreno-Cárdenas AB; Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
  • Arenillas C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Bernatowicz K; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Comas R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Li S; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Kodack DP; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain.
  • Fasani R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Garcia A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Gonzalo-Ruiz J; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
  • Piris-Gimenez A; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Kerr G; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Intini R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Montagna A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Germani MM; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Randon G; Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland.
  • Vivancos A; Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy.
  • Smits R; Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy.
  • Graus D; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Perez-Lopez R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cremolini C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Lonardi S; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
  • Pietrantonio F; Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland.
  • Dienstmann R; Ridgeline Discovery, Basel, Switzerland.
  • Tabernero J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Toledo RA; Radiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Nat Med ; 28(10): 2162-2170, 2022 Oct.
Article in En | MEDLINE | ID: mdl-36097219
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Ubiquitin-Protein Ligases Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / Ubiquitin-Protein Ligases Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2022 Type: Article